Literature DB >> 23349300

Different effects of HLA disparity on transplant outcomes after single-unit cord blood transplantation between pediatric and adult patients with leukemia.

Yoshiko Atsuta1, Junya Kanda, Minoko Takanashi, Yasuo Morishima, Shuichi Taniguchi, Satoshi Takahashi, Hiroyasu Ogawa, Kazuteru Ohashi, Yuju Ohno, Yasushi Onishi, Nobuyuki Aotsuka, Tokiko Nagamura-Inoue, Koji Kato, Yoshinobu Kanda.   

Abstract

Recent advances in unrelated cord blood transplantation have increased chances and options available in allogeneic stem cell transplantation. The effect of HLA disparity on outcomes after cord blood transplantation was studied recently in mainly pediatric populations. Results showed that HLA matching in combination with total nucleated cell dose positively affects survival. The effect of HLA disparity after single-unit cord blood transplantation may be different in adults because their total nucleated cell dose is much lower compared to pediatric patients. We investigated the effect of HLA disparity on the outcome of single-unit unrelated cord blood transplantation separately in 498 children aged 15 years or under (HLA-A, HLA-B low-resolution, and HLA-DRB1 high-resolution matched [6/6], n=82, and one locus- [5/6], n=222, two loci- [4/6], n=158, three loci- [3/6] mismatched, n=36) and 1,880 adults (6/6, n=71; 5/6, n=309; 4/6, n=1,025; 3/6, n=475) with leukemia. With adjusted analyses, in children, 4/6 showed significantly increased risks of overall mortality (relative risk [RR]=1.61, P=0.042) and transplant-related mortality (RR=3.55, P=0.005) compared to 6/6. The risk of grade 2 to 4 acute GVHD was increased in 5/6 (RR=2.13, P=0.004) and 4/6 (RR=2.65, P<0.001). In adults, the risk of mortality did not increase with the number of mismatched loci (RR=0.99, P=0.944 for 5/6; RR=0.88, P=0.436 for 4/6). The risk of relapse was significantly decreased in 4/6 (RR=0.67, P=0.034). The risk of transplant-related mortality (TRM) or acute GVHD was not increased in 5/6 or 4/6. The effect of HLA disparity on transplant outcome differed between children and adults. In children, an increased number of mismatched HLA loci correlated with an increased risk of mortality. In adults, there was no increase in mortality with an increase in the number of mismatched HLA loci.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23349300      PMCID: PMC3640130          DOI: 10.3324/haematol.2012.076042

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  35 in total

Review 1.  Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part I: unadjusted analysis.

Authors:  J P Klein; J D Rizzo; M J Zhang; N Keiding
Journal:  Bone Marrow Transplant       Date:  2001-11       Impact factor: 5.483

Review 2.  Pathophysiology and treatment of graft-versus-host disease.

Authors:  M E Flowers; E Kansu; K M Sullivan
Journal:  Hematol Oncol Clin North Am       Date:  1999-10       Impact factor: 3.722

3.  The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors.

Authors:  Yasuo Morishima; Takehiko Sasazuki; Hidetoshi Inoko; Takeo Juji; Tatsuya Akaza; Ken Yamamoto; Yoshihide Ishikawa; Shunichi Kato; Hiroshi Sao; Hisashi Sakamaki; Keisei Kawa; Nobuyuki Hamajima; Shigetaka Asano; Yoshihisa Kodera
Journal:  Blood       Date:  2002-06-01       Impact factor: 22.113

4.  Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia.

Authors:  V Rocha; J Cornish; E L Sievers; A Filipovich; F Locatelli; C Peters; M Remberger; G Michel; W Arcese; S Dallorso; K Tiedemann; A Busca; K W Chan; S Kato; J Ortega; M Vowels; A Zander; G Souillet; A Oakill; A Woolfrey; A L Pay; A Green; F Garnier; I Ionescu; P Wernet; G Sirchia; P Rubinstein; S Chevret; E Gluckman
Journal:  Blood       Date:  2001-05-15       Impact factor: 22.113

5.  Survival after transplantation of unrelated donor umbilical cord blood is comparable to that of human leukocyte antigen-matched unrelated donor bone marrow: results of a matched-pair analysis.

Authors:  J N Barker; S M Davies; T DeFor; N K Ramsay; D J Weisdorf; J E Wagner
Journal:  Blood       Date:  2001-05-15       Impact factor: 22.113

6.  Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources.

Authors:  V Rocha; J E Wagner; K A Sobocinski; J P Klein; M J Zhang; M M Horowitz; E Gluckman
Journal:  N Engl J Med       Date:  2000-06-22       Impact factor: 91.245

7.  Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival.

Authors:  John E Wagner; Juliet N Barker; Todd E DeFor; K Scott Baker; Bruce R Blazar; Cindy Eide; Anne Goldman; John Kersey; William Krivit; Margaret L MacMillan; Paul J Orchard; Charles Peters; Daniel J Weisdorf; Norma K C Ramsay; Stella M Davies
Journal:  Blood       Date:  2002-09-01       Impact factor: 22.113

8.  Graft-versus-leukemia reactions after bone marrow transplantation.

Authors:  M M Horowitz; R P Gale; P M Sondel; J M Goldman; J Kersey; H J Kolb; A A Rimm; O Ringdén; C Rozman; B Speck
Journal:  Blood       Date:  1990-02-01       Impact factor: 22.113

9.  Bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: importance of a graft-versus-leukaemia effect.

Authors:  J F Apperley; F R Mauro; J M Goldman; W Gregory; C K Arthur; J Hows; W Arcese; G Papa; F Mandelli; D Wardle
Journal:  Br J Haematol       Date:  1988-06       Impact factor: 6.998

Review 10.  1994 Consensus Conference on Acute GVHD Grading.

Authors:  D Przepiorka; D Weisdorf; P Martin; H G Klingemann; P Beatty; J Hows; E D Thomas
Journal:  Bone Marrow Transplant       Date:  1995-06       Impact factor: 5.483

View more
  17 in total

1.  A prospective investigation of cell dose in single-unit umbilical cord blood transplantation for adults with high-risk hematologic malignancies.

Authors:  U Sobol; A Go; S Kliethermes; S Bufalino; T Rodriguez; S Smith; M Parthasarathy; P Stiff
Journal:  Bone Marrow Transplant       Date:  2015-09-14       Impact factor: 5.483

2.  Scripts for TRUMP data analyses. Part II (HLA-related data): statistical analyses specific for hematopoietic stem cell transplantation.

Authors:  Junya Kanda
Journal:  Int J Hematol       Date:  2015-11-20       Impact factor: 2.490

3.  Efficiency of high-dose cytarabine added to CY/TBI in cord blood transplantation for myeloid malignancy.

Authors:  Yasuyuki Arai; June Takeda; Kazunari Aoki; Tadakazu Kondo; Satoshi Takahashi; Yasushi Onishi; Yukiyasu Ozawa; Nobuyuki Aotsuka; Yasuji Kouzai; Hirohisa Nakamae; Shuichi Ota; Chiaki Nakaseko; Hiroki Yamaguchi; Koji Kato; Yoshiko Atsuta; Akiyoshi Takami
Journal:  Blood       Date:  2015-06-01       Impact factor: 22.113

4.  Impact of Allele-Level HLA Mismatch on Outcomes in Recipients of Double Umbilical Cord Blood Transplantation.

Authors:  Claudio G Brunstein; Effie W Petersdorf; Todd E DeFor; Harriet Noreen; David Maurer; Margaret L MacMillan; Celalettin Ustun; Michael R Verneris; Jeffrey S Miller; Bruce R Blazar; Philip B McGlave; Daniel J Weisdorf; John E Wagner
Journal:  Biol Blood Marrow Transplant       Date:  2015-09-30       Impact factor: 5.742

5.  Long-term outcome and prognostic factors of unrelated cord blood transplantation in children with haematological malignancies: a retrospective study using the Spanish Working Party for BMT in Children (GETMON) database.

Authors:  C Díaz de Heredia; M González; A Verdeguer; I Elorza; A Rodriguez; A Martinez; J M Pérez; I Badell; M E Gonzalez; T Olivé; J M Fernández; M S Maldonado; M A Díaz; J Sánchez de Toledo
Journal:  Bone Marrow Transplant       Date:  2014-03-10       Impact factor: 5.483

6.  Single umbilical cord blood with or without CD34+ cells from a third-party donor in adults with leukemia.

Authors:  Jaime Sanz; Mi Kwon; Guiomar Bautista; Miguel A Sanz; Pascual Balsalobre; José Luis Piñana; Carlos Solano; Rafael Duarte; Christelle Ferrá; Ignacio Lorenzo; Carmen Martín; Pere Barba; María Jesús Pascual; Rodrigo Martino; Jorge Gayoso; Ismael Buño; Carmen Regidor; Almudena de la Iglesia; Juan Montoro; José Luis Díez-Martín; Guillermo F Sanz; Rafael Cabrera
Journal:  Blood Adv       Date:  2017-06-20

7.  Risk factors and organ involvement of chronic GVHD in Japan.

Authors:  J Kanda; H Nakasone; Y Atsuta; T Toubai; H Yokoyama; T Fukuda; S Taniguchi; K Ohashi; H Ogawa; T Eto; K Miyamura; Y Morishima; T Nagamura-Inoue; H Sakamaki; M Murata
Journal:  Bone Marrow Transplant       Date:  2013-09-30       Impact factor: 5.483

8.  Graft-versus-host disease and survival after cord blood transplantation for acute leukemia: a comparison of Japanese versus White populations.

Authors:  Yachiyo Kuwatsuka; Yoshiko Atsuta; Mary M Horowitz; Jiro Inagaki; Junya Kanda; Koji Kato; Katsuyoshi Koh; Mei-Jie Zhang; Mary Eapen
Journal:  Biol Blood Marrow Transplant       Date:  2014-02-10       Impact factor: 5.742

9.  Single cord blood transplantation for acute myeloid leukemia patients aged 60 years or older: a retrospective study in Japan.

Authors:  Masamichi Isobe; Takaaki Konuma; Masayoshi Masuko; Naoyuki Uchida; Shigesaburo Miyakoshi; Yasuhiro Sugio; Shuro Yoshida; Masatsugu Tanaka; Yoshiko Matsuhashi; Norimichi Hattori; Makoto Onizuka; Nobuyuki Aotsuka; Yasushi Kouzai; Atsushi Wake; Takafumi Kimura; Tatsuo Ichinohe; Yoshiko Atsuta; Masamitsu Yanada
Journal:  Ann Hematol       Date:  2021-02-23       Impact factor: 3.673

10.  Myeloablative cord blood transplantation in adults with acute leukemia: comparison of two different transplant platforms.

Authors:  Jaime Sanz; John E Wagner; Miguel A Sanz; Todd DeFor; Pau Montesinos; Veronika Bachanova; Ignacio Lorenzo; Erica Warlick; Guillermo F Sanz; Claudio Brunstein
Journal:  Biol Blood Marrow Transplant       Date:  2013-09-30       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.